Market closed

DiaMedica Therapeutics Inc. Common Stock/$DMAC

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About DiaMedica Therapeutics Inc. Common Stock

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Ticker

$DMAC

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Minneapolis, United States

Employees

Website

www.diamedica.com

DMAC Metrics

BasicAdvanced

$212M

-

-$0.55

1.46 -

Price and volume

Market cap

$212M

Beta

1.46

52-week high

$6.41

52-week low

$2.14

Average daily volume

101K

Financial strength

Current ratio

11.815

Quick ratio

11.749

Long term debt to equity

0.548

Total debt to equity

0.761

Management effectiveness

Return on assets (TTM)

-27.23%

Return on equity (TTM)

-41.90%

Valuation

Price to book

4.42

Price to tangible book (TTM)

4.42

Price to free cash flow (TTM)

-9.985

Growth

Earnings per share change (TTM)

-8.59%

3-year earnings per share growth (CAGR)

-10.50%

What the Analysts think about DMAC

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for DiaMedica Therapeutics Inc. Common Stock stock.

DMAC Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

DMAC Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

DMAC News

AllArticlesVideos

DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

Business Wire·2 months ago

DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

Business Wire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DMAC

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for DiaMedica Therapeutics Inc. Common Stock stock?

DiaMedica Therapeutics Inc. Common Stock (DMAC) has a market cap of $212M as of January 15, 2025.

What is the P/E ratio for DiaMedica Therapeutics Inc. Common Stock stock?

The price to earnings (P/E) ratio for DiaMedica Therapeutics Inc. Common Stock (DMAC) stock is 0 as of January 15, 2025.

Does DiaMedica Therapeutics Inc. Common Stock stock pay dividends?

No, DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next DiaMedica Therapeutics Inc. Common Stock dividend payment date?

DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders.

What is the beta indicator for DiaMedica Therapeutics Inc. Common Stock?

DiaMedica Therapeutics Inc. Common Stock (DMAC) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.